Last reviewed · How we verify

Ascites replacement with albumin and hartmann's solution

Seoul National University Hospital · FDA-approved active Small molecule Quality 0/100

Ascites replacement with albumin and hartmann's solution is a Small molecule drug developed by Seoul National University Hospital. It is currently FDA-approved. Also known as: Experimental.

At a glance

Generic nameAscites replacement with albumin and hartmann's solution
Also known asExperimental
SponsorSeoul National University Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ascites replacement with albumin and hartmann's solution

What is Ascites replacement with albumin and hartmann's solution?

Ascites replacement with albumin and hartmann's solution is a Small molecule drug developed by Seoul National University Hospital.

Who makes Ascites replacement with albumin and hartmann's solution?

Ascites replacement with albumin and hartmann's solution is developed and marketed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).

Is Ascites replacement with albumin and hartmann's solution also known as anything else?

Ascites replacement with albumin and hartmann's solution is also known as Experimental.

What development phase is Ascites replacement with albumin and hartmann's solution in?

Ascites replacement with albumin and hartmann's solution is FDA-approved (marketed).

Related